Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diethyl Ether→

Diethyl Ether Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
60-29-7
Molecular formula
C4H10O
Molecular weight
74.12 g/mol
Drug class
Volatile inhalational anaestheticcentral nervous system depressant (historical)
Mechanism of action
Produces general anaesthesia through non-specific CNS depression and modulation of multiple ion channels and neurotransmitter systems, including enhancement of inhibitory transmission. It is highly flammable and has been superseded by safer modern anaesthetics.
Indications / reported uses
  • Historical use as an inhalational general anaesthetic. Diethyl ether is not a routine contemporary anaesthetic because of flammability, airway irritation and safety concerns. Non-anaesthetic historical uses should not be assigned as current therapeutic indications.

Sources: NLM MeSH — Diethyl ether · PubMed — Diethyl ether anaesthesia history · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diethyl Ether Environmental Risk Assessment (ERA) (the Diethyl Ether ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.